Back to results
US 2018/0002436 A1Published application
Targeted tgfß inhibition
AssigneeMerck Patent GmbH
InventorKin-Ming Lo
Life of this patent
Estimating the term…
Abstract
This invention relates generally to bifunctional molecules including (a) a TGFβRII or fragment thereof capable of binding TGFβ and (b) an antibody, or antigen binding fragment thereof, that binds to an immune checkpoint protein, such as Programmed Death Ligand 1 (PD-L1), uses of such molecules (e.g., for treating cancer), and methods of making such molecules.
Claims15
A protein comprising:
- a) human TGFβRII, or a fragment thereof capable of binding TGFβ;
- and
- b) an antibody, or an antigen-binding fragment thereof, that binds human protein Programmed Death Ligand 1 (PD-L1).
A polypeptide comprising:
- a) at least a variable domain of a heavy chain of an antibody that binds human protein Programmed Death Ligand 1 (PD-L1);
- and
- b) human TGFβRII, or a fragment thereof capable of binding TGFβ.
15-35. (canceled)
Dependencies are inferred from the claim text.